Stifel Nicolaus Boosts Diploma (LON:DPLM) Price Target to GBX 6,800

Diploma (LON:DPLM) had its price target increased by equities researchers at Stifel Nicolaus from GBX 6,200 to GBX 6,800 in a report released on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price target points to a potential upside of 19.03% from the company’s previous close.

Several other analysts have also commented on the company. Deutsche Bank Aktiengesellschaft lifted their price objective on Diploma from GBX 6,000 to GBX 6,200 and gave the stock a “buy” rating in a report on Wednesday, January 14th. Shore Capital Group reissued a “hold” rating on shares of Diploma in a report on Wednesday. Berenberg Bank reissued a “buy” rating and issued a GBX 6,350 target price on shares of Diploma in a research report on Wednesday, November 19th. Finally, Peel Hunt restated a “buy” rating and set a GBX 6,150 price target on shares of Diploma in a research note on Friday, December 19th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Diploma currently has an average rating of “Moderate Buy” and an average target price of GBX 6,023.75.

Diploma Price Performance

Shares of DPLM opened at GBX 5,712.95 on Thursday. The firm has a fifty day simple moving average of GBX 5,457.51 and a two-hundred day simple moving average of GBX 5,425.55. The firm has a market cap of £7.66 billion, a PE ratio of 41.61, a P/E/G ratio of 2.82 and a beta of 1.03. The company has a current ratio of 2.04, a quick ratio of 0.80 and a debt-to-equity ratio of 46.97. Diploma has a 1-year low of GBX 3,532 and a 1-year high of GBX 6,019.52.

Insider Activity

In related news, insider Katie Bickerstaffe bought 352 shares of the firm’s stock in a transaction that occurred on Wednesday, January 14th. The shares were bought at an average cost of GBX 5,645 per share, with a total value of £19,870.40. Also, insider Johnny Thomson sold 30,000 shares of Diploma stock in a transaction on Friday, January 16th. The shares were sold at an average price of GBX 5,668, for a total value of £1,700,400. Insiders own 1.14% of the company’s stock.

Key Headlines Impacting Diploma

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Surprise profit upgrade forced a re‑rating of consensus and sparked a ~17% share jump as investors digested stronger-than-expected guidance. Diploma shares surge 17% as surprise profit upgrade exposes the bearish consensus
• Positive Sentiment: Guidance upgrade lifted Diploma’s earnings forecasts (~15%) and prompted price-target increases (headline 6,600p), reinforcing the bullish re-rate. Diploma price target lifted to 6,600p after guidance upgrade drives 15% earnings forecast rise
• Positive Sentiment: Berenberg raised its price target sharply to GBX 7,500 and moved to a “buy” rating, signaling confidence in the upgraded outlook. Broker ratings
• Positive Sentiment: Stifel increased its target to GBX 6,800 and upgraded to “buy”, adding to the cluster of upward revisions from brokers. Broker ratings
• Positive Sentiment: Deutsche Bank raised its target to GBX 6,400 and now carries a “buy” stance, supporting the upward momentum. Broker ratings
• Positive Sentiment: Royal Bank of Canada lifted its target to GBX 6,600 and set an “outperform” rating — another well‑known house backing the upgraded story. RBC note
• Negative Sentiment: Shore Capital reaffirmed a “hold” rating on 20 March, which may have damped some of the rally and encouraged profit‑taking after the sharp run. Shore Capital Group Reaffirms Hold Rating for Diploma

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.